Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients

Journal of the Peripheral Nervous System

Volumn 15, Issue 1, 2010, Pages 17-25

  Velasco, Roser ^a,b   Petit, Josep ^c   Clapés, Victoria ^c   Verdú, Enric ^b   Navarro, Xavier ^b   Bruna, Jordi ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

Bortezomib; CIPN; Peripheral neuropathy; Total neuropathy score; Toxic neuropathy

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LACTATE DEHYDROGENASE; MELPHALAN; VINCRISTINE;

ADULT; AGED; ARTICLE; ATROPHY; CONTROLLED STUDY; ELECTRODIAGNOSIS; FEMALE; HUMAN; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MOTOR NERVE CONDUCTION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NERVE CONDUCTION; NERVE POTENTIAL; NEUROLOGIC EXAMINATION; NEUROPHYSIOLOGY; OVERALL SURVIVAL; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL NEUROPATHY; PERONEUS NERVE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SENSORY NERVE;

AGE FACTORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BORONIC ACIDS; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEUROLOGIC EXAMINATION; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEASE INHIBITORS; PYRAZINES; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VINCRISTINE;

EID: 77649247949     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2010.00248.x     Document Type: Article

References (36)

1. Argyrou AA, Iconomou G, Kalofonos HP (2008). Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112 : 1593 1599.
2. Awada A, Albanell J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascon P, Piccart MJ, Baselga J (2008). Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer 98 : 1500 1507.
3. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG (2007). Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110 : 1042 1049.
4. Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, Suh C, Sohn SK, Min YH, Lee JJ, Kim K, Seong CM, Yoon HJ, Cho KS, Jo DY, Lee KH, Lee NR, Kim CS, Korean Multiple Myeloma Working Party (2006). A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. Int J Hematol 83 : 309 313.
5. Bruna J, Udina E, Alé A, Monbaliu J, Verdú E, Vynckier A, Silverman L, Navarro X (2009). Neurophysiological and histological characterization of bortezomib-induced neuropathy in mice. J Peripher Nerv Syst 14 (Suppl. 2 22.
6. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Parma G, Lissoni A, Fei F, Cundari S, Zanna C (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology 61 : 1297 1300.
7. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D'Incalci M, De Coster R (2007a). Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 204 : 317 325.
8. Cavaletti G, Nobile-Orazio E (2007b). Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 92 : 1308 1310.
9. Casafont I, Berciano MT, Lafarga M (2009). Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res 17 : 167 178.
10. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T (1999). Total neuropathy score: validation and reliability study. Neurology 53 : 1660 1664.
11. Corso A, Mangiacavalli S, Varettoni M, Pascutto C, Zappasodi P, Lazzarino M (2009). Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res 10, in press.
12. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I (2008). Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Sys 13 : 275 282.
13. Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR, Southwest Oncology Group (2009). Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 4 : 87 92.
14. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working Group (2006). International uniform response criteria for multiple myeloma. Leukemia 20 : 1467 1473. (Pubitemid 44264086)
15. El-Cheikh J, Stoppa AM, Bouabdallah R, de Lavallade H, Coso D, de Collela JM, Auran-Schleinitz T, Gastaut JA, Blaise D, Mohty M (2008). Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced myeloma. Clin Lymphoma Myeloma 8 : 146 152.
16. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, Cohen JA, Fisher MA, Howard JF, Kinsella LJ, Latov N, Lewis RA, Low PA, Sumner AJ, American Academy of Neurology, American Association of Electrodiagnostic Medicine, American Academy of Physical Medicine and Rehabilitation (2005). Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 64 : 199 207.
17. Filosto M, Rossi G, Pelizzari AM, Buzio S, Tentorio M, Broglio L, Mancuso M, Rinaldi M, Scarpelli M, Padovani A (2007). A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement. J Neurol Sci 263 : 40 43.
18. Gupta S, Pagliuca A, Devereux S, Mufti GJ, Schey S (2006). Life-threatening motor neurotoxicity in association with bortezomib. Haematologica 91 : 1001.
19. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, Hulin C, Benboubker L, Fuzibet JG, Renaud M, Moreau P, Avet-Loiseau H (2006). Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91 : 1498 1505.
20. Hughes R (2008). NCI-CTC vs TNS: which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy? Nat Clin Pract Neurol 4 : 68 69.
21. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R (2007). Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13 : 5291 5294.
22. Lanzani F, Mattavelli L, Frigeni B, Rossini F, Cammarota S, Petrò D, Jann S, Cavaletti G (2008). Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst 13 : 267 274.
23. Legha SS (1986). Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1 : 421 427.
24. Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF (2006). Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108 : 2165 2172.
25. Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A, Ceresa C, Avezza F, Crippa L, Marmiroli P, Cavaletti G (2009). Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 18, in press.
26. Millenium Pharmaceuticals, Inc 2004). Velcade TM (bortezomib) for Injection. Prescribing Information. Millenium Pharmaceuticals, Inc., Cambridge, MA.
27. Min CK, Lee MJ, Eom KS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Lim J, Kim Y, Han K (2007). Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone. Jpn J Clin Oncol 37 : 961 968.
28. Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S, Singer C, Harding S, Foot N, Hallam S, Odeh L, Joel S, Cavenagh J (2009). Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol 144 : 887 894.
29. Postma TJ, Heimans JJ (2000). Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11 : 509 513.
30. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. N Eng J Med 348 : 2609 2617.
31. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006). Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24 : 3113 3120.
32. Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA (2009a). Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27 : 3518 3525.
33. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J (2009b). Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144 : 895 903.
34. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG, VISTA Trial Investigators (2008). Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Eng J Med 359 : 906 917.
35. Stubblefield MD, Slovin S, MacGregor-Cortelli B, Muzzy J, Scher H, Wright J, Esseltine D, Schenkein D, O'Connor OA (2006). An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clin Oncol (R Coll Radiol) 18 : 410 418.
36. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003). CTCAEv3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 : 176 181. (Pubitemid 36962641)